Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.
Wang Y, Situ X, Cardenas H, Siu E, Alhunayan SA, Keathley R, Tanner E, Wei JJ, Tan Y, Prabhu Dessai CV, Cheng JX, Matei D.
Wang Y, et al. Among authors: matei d.
Clin Cancer Res. 2024 Mar 15;30(6):1175-1188. doi: 10.1158/1078-0432.CCR-23-2368.
Clin Cancer Res. 2024.
PMID: 38231483